-
Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China
•
The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE: TEVA) innovative chemical drug Copaxone (glatiramer acetate) has been approved for use as a treatment for multiple sclerosis (MS) in China. This marks the second MS therapy available in China following Bristol-Myers Squibb (BMS, NYSE:…
-
Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of the Sisram Wellness Center in Chicago, United States, by its medical aesthetic solutions unit Sisram (HKG: 1696). This new venture marks the company’s expansion into providing comprehensive beauty and health experience services. Services Offered at…
-
Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics
•
China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine Co., Ltd (SHE: 000963), expanding their strategic partnership initially formed in November 2020. The agreement focuses on the co-development of innovative bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), marking a significant step forward in…
-
Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu
•
South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has been filed in China for Fexuclu/Abcito (fexuprazan) in a 40mg dosage form. Fexuclu, an in-house developed potassium-competitive acid blocker (P-CAB), represents a new generation of therapies for gastroesophageal reflux disease (GERD). Advantages of P-CABs Over…
-
Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone
•
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate, INS018_055, has completed first dosing in patients in a Phase II clinical trial. This small-molecule, oral anti-fibrotic drug, entirely generated by Insilico’s AI platforms, is hailed as the world’s first AI-discovered molecule to reach the…
-
Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions
•
Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar candidate BAT2206 from China’s Bio-Thera Solutions (SHA: 688177). This biosimilar candidate references Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary Janssen’s immunosuppressant Stelara (ustekinumab). The agreement builds upon a previous licensing and supply deal from 2020…
-
AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received market approval from the National Medical Products Administration (NMPA) in China for its fixed dose combination of dapagliflozin and metformin, a treatment for type 2 diabetes. This once-daily compound is now the only sustained-release formulation in China…
-
Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction
•
Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2 financing round, raising RMB 300 million (USD 42 million). The investment was led by Guangzhou Industrial Investment and Capital, Guoju Venture Capital, and CSPC Pharmaceutical Group. The funds will be allocated towards advancing clinical studies,…
-
LianBio’s Mavacamten Receives Priority Review Status from China’s CDE for oHCM Treatment
•
The Center for Drug Evaluation (CDE) has indicated on its website that China-based biotech firm LianBio (Nasdaq: LIAN) has been awarded priority review status for its drug mavacamten. This status is for the treatment of adult patients with symptomatic New York Heart Association (NYHA) heart function II-III obstructive hypertrophic cardiomyopathy…
-
CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from the National Medical Products Administration (NMPA) to commence a clinical study for its in-house developed Category 1 antibody, JMT203. This marks a significant step forward in the development of this novel treatment for cancer cachexia.…
-
BDgene Technology Secures Over RMB 200 Million in Series B Financing Led by Lapam Capital
•
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million (USD 27.7 million) in a Series B financing round. The round was led by Lapam Capital, with additional investments from Penglai Capital, Hermed Capital, Sunland Fund, and Sprinvest. The funds raised will be allocated towards…
-
WuXi Biologics Partners with Pharmadule Morimatsu AB for CRDMO Expansion in Singapore
•
China-based WuXi Biologics (HKG: 2269) has announced a strategic partnership with Sweden-headquartered Pharmadule Morimatsu AB (HKG: 2155), focusing on the expansion of its Contract Research, Development, and Manufacturing Organization (CRDMO) service center in Singapore. The collaboration encompasses key project lifecycle processes, including design, manufacturing, FAT (Factory Acceptance Test), installation, debugging,…
-
CStone Pharmaceuticals’ Gavreto Approved for First-Line RET Fusion-Positive NSCLC Treatment in China
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) of China has granted approval for a supplemental new drug application (sNDA) for Gavreto (pralsetinib). This approval is for the first-line treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC).…
-
CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration (NMPA) has accepted a market filing for its biosimilar version of Novartis’ (NYSE: NVS) Xolair (omalizumab) for review. This development marks a significant step towards expanding treatment options for patients with allergic asthma and chronic…
-
Henlius Biotech’s HLX13 Biosimilar Gets NMPA Approval for Liver Cancer Clinical Trial
•
Shanghai Henlius Biotech, Inc (HKG: 2696) has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its HLX13, a biosimilar of US major Bristol-Myers Squibb’s (BMS, NYSE: BMY) Yervoy (ipilimumab), for the treatment of liver cancer. HLX13: A CTLA-4 Monoclonal Antibody for Cancer TreatmentsHLX13 is a…
-
Chia Tai Tianqing Launches First Batch of F-627 for Neutropenia Treatment in China
•
China-based Chia Tai Tianqing has announced the first batch prescriptions in China for its efbemalenograstim alfa (F-627), an in-house developed long-acting recombinant human granulocyte colony stimulating factor (rhGCSF)-Fc fusion protein. The drug is indicated for the prevention and treatment of neutropenia during chemotherapy in cancer patients. F-627 received marketing approval…
-
Jiangsu Kanion Pharmaceutical Gets FDA Approval for KYS202002A Clinical Study in Multiple Myeloma
•
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving the green light from the US Food and Drug Administration (FDA) to conduct a clinical study for its pipeline candidate KYS202002A, focusing on recurrent/refractory multiple myeloma (R/R MM). This follows the molecule’s approval for clinical trials in China in…
-
Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia
•
Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA: 688177) for bevacizumab (BAT1706), a biosimilar version of Roche’s (SWX: ROG) Avastin (bevacizumab). According to the agreement, Mega Lifesciences obtains exclusive distribution and marketing rights to the product in Indonesia, while Bio-Thera will handle the…
-
Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced receiving another indication approval for its drug dalpiciclib (SHR6390). The approval is for use as an initial therapy combined with an aromatase inhibitor for patients with hormone receptor (HR) positive, human epidermal growth factor…
-
Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma
•
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Gilead (NASDAQ: GILD) subsidiary Kite Pharma, has announced that its product Yescarta (axicabtagene ciloleucel) has obtained marketing approval from the National Medical Products Administration (NMPA) for a new indication…
